CoronaryAtlas logo
CoronaryAtlas
Immunoglobulin M
Pathway / Lipid retention & oxidation

Immunoglobulin M

protein

IgM autoantibodies targeting oxidized lipoproteins suppress lipid retention and promote clearance of modified LDL, reducing plaque burden.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleClears oxidized LDL; atheroprotective via modified-lipoprotein targeting.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — non-Type-I
48
A — assay feasibility
68
E — evidence strength
28
T1DI (composite)
6
Specificity differential (R−C)-32.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 1
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 1
Coverage: 7/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 8 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(4)